N-acetylsulfanilyl chloride
- Generic Name
- N-acetylsulfanilyl chloride
- Drug Type
- Small Molecule
- Chemical Formula
- C8H8ClNO3S
- CAS Number
- 121-60-8
- Unique Ingredient Identifier
- LIX4M9AIVM
- Background
ASC has been investigated for the screening of Patients Undergoing Screening or Surveillance Colonoscopy.
NASH Treatment Market to Reach Significant Growth by 2032, Driven by Emerging Therapies
• The non-alcoholic steatohepatitis (NASH) market is poised for substantial growth, projected to expand significantly by 2032 across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
• This growth is fueled by the introduction of novel therapies targeting NASH, with several drugs in Phase II and Phase III clinical trials showing promise for improving treatment outcomes.
• Key players such as Madrigal Pharmaceuticals, Intercept Pharmaceuticals, and Novo Nordisk are actively developing innovative treatments, contributing to a dynamic and competitive market landscape.
• The increasing prevalence of NASH and the growing understanding of its pathophysiology are driving the demand for effective therapies, creating opportunities for pharmaceutical companies.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath